Revolution Medicines Q3 2026 net loss widens 34% to $407.5 million
Bitget2026/11/04 21:10- Revolution Medicines’ third-quarter 2026 net loss widened 34% year over year to $407.5 million.
- RASONQUE net product revenue reached $197.6 million, reflecting approximately five weeks of commercial availability following U.S. FDA approval.
- Research and development expenses rose 59% year over year to $417.1 million; selling, general and administrative expenses nearly tripled to $153.3 million.
- A positive CHMP opinion recommended daraxonrasib’s approval for previously treated metastatic pancreatic cancer in the European Union.
- Full-year 2026 GAAP operating expense guidance remained unchanged at $2.1 billion to $2.2 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
